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Immunization1. Introduction
Streptococcus pneumoniae (the pneumococcus) continues to be
responsible for major morbidity and mortality worldwide, causing a
broad spectrum of diseases including otitis media (OM), pneumonia,
bacteraemia andmeningitis (WHO, 2014a, 2015). The prevalence of an-
tibiotic-resistant pneumococci is increasing rapidly (WHO, 2014b), and
available capsular-based vaccines are expensive and have major short-
comings with respect to immunogenicity, serotype replacement
and/or strain coverage (Olarte et al., 2015). This has stimulated global
efforts towards the development of cheaper, non-serotype-dependent
vaccines based on conserved pneumococcal virulence proteins. However,University of Southern
sh Columbia, Vancouver,
ance Ecology, School of
371, Australia.
s an open access article underprotein antigens currently under consideration are being selected solely
on the basis of their capacity to elicit protection inmodels of pneumonia
and bacteremia, but their ability to protect against colonization of the
nasopharynx, OM and meningitis is unproven (Ogunniyi and Paton,
2015).
Asymptomatic colonization of the nasopharynx almost invariably
precedes disease; however, pneumococci vary in their capacity to
colonize the nasopharynx, both in humans and in animal models.
Certain serotypes and/or clonal groups are more often isolated from
carriers, while others are more often isolated from sterile sites
(Brueggemann et al., 2003; Sandgren et al., 2004; Sjostrom et al.,
2006). In the context of rational pneumococcal protein vaccine design,
an ideal vaccine formulation will reduce colonization as well as prevent
invasive pneumococcal disease (Paton and Ogunniyi, 2011). A number
of pneumococcal proteins have been shown to protect against coloniza-
tion in addition to their protective capacities against invasive disease in
animal models. Foremost among these are maltose/maltodextrin ABC
transporter binding protein (MalX) (Moffitt et al., 2011), Neuraminidase
A (NanA) (Tong et al., 2005), and pneumococcal surface proteins A and
C (PspA and PspC) (Balachandran et al., 2002;Wu et al., 1997). Neverthe-
less, novel candidate proteins continue to be identified and appraised for
inclusion in multi-component pneumococcal protein vaccines that are
currently under development.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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croarray analyses to identify the factors that trigger progression fromcol-
onization to invasive or meningeal infection in a murine model. One of
these genes, glpO, encoding the pneumococcal alpha-glycerophosphate
oxidase (herein designated SpGlpO), was found to be upregulated in
the brain versus blood of mice, and contributes significantly to the
development of meningitis. Preliminary analysis also revealed that a
pneumococcal glpO deletion mutant was significantly attenuated for na-
sopharyngeal colonization relative to the isogenicwild type (Mahdi et al.,
2012). Given this important finding, we carried out a detailed analysis of
the role of SpGlpO in colonization, assessed its vaccine potential against
pneumococcal carriage in a murine model, and examined its role in the
host-pathogen interaction.
2. Materials and Methods
2.1. Bacterial Strains and Growth Conditions
The pneumococcal strains used in this study were serotype 6A
(WCH16), serotype 4 (WCH43), and their isogenicΔglpOmutant deriv-
atives (Table S1). Serotype-specific capsule production was confirmed
by Quellung reaction, as described previously (Berry and Paton, 2000).
Bacteria were grown statically at 37 °C in serum broth (SB; 10% heat-
inactivated horse serum in nutrient broth) to A600 nm of 0.16 (equivalent
to approx. 5 × 107 CFU/ml).
2.2. Mice
Outbred 5- to 6-week-old female CD1 (Swiss) mice, obtained from
the Laboratory Animal Services specific pathogen-free breeding facility
of The University of Adelaide, were used in all experiments and were
housed in the same facility for the entire duration of the experiments.
Animals were provided with food and water ad libitum. The Animal
Ethics Committee of The University of Adelaide approved all animal ex-
periments (approval numbers S-2010-001 and S-2013-053). The study
was conducted in compliance with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes (7th Edition 2004
and 8th Edition 2013) and the South Australian Animal Welfare Act
1985. Animal experimentation were conducted in accordance with AR-
RIVE guidelines for animal research.
2.3. Mixed Infection Experiments
For in vivo competition experiments, mutant and wild type bacteria
weremixed at an input ratio of 1:1, and groups of micewere challenged
intranasally (i.n.) under anesthesia with 50 μl mixed bacterial suspen-
sion containing approx. 2.5 × 106 CFU each strain in SB. At 48 and
72h post-challenge, 14–16mice fromeachmixed inoculumexperiment
were sacrificed, and thebacterial load for each strain in thenasopharynx
was quantitated as described previously (Ogunniyi et al., 2012). A 40 μl
aliquot of each sample was serially diluted in SB and plated on blood
agar and blood agar with a selective antibiotic marker (spectinomycin
resistance) carried by the ΔglpO deletion mutant to determine the
ratio of mutant towild type bacteria. Competitive indices were calculat-
ed as the ratio ofmutant towild type bacteria recovered, adjusted by the
input ratio. Differences in colonization between wild type and mutant
were analyzed by one-sample t-test (two-tailed). A P value of b0.05
was considered statistically significant.
2.4. Adherence Assays
Adherence of pneumococci to human nasopharyngeal carcinomaep-
ithelial (Detroit 562) cells (ATCC®CCL 138™)was assayed essentially as
described previously (Mahdi et al., 2012). Cells weremaintained in a 1:1
mixture of Dulbecco's Modified Eagle Medium (DMEM, and Ham's F-12
medium (Gibco; Cat No: 11320–033), supplemented with 10% (v/v)heat-inactivated fetal calf serum (FCS), 25 mM HEPES, 100 U per ml
penicillin-streptomycin. Strains were grown in C + Y medium (Lacks
and Hotchkiss, 1960) supplemented with 1% glycerol (instead of glu-
cose) for maximal SpGlpO expression and diluted to approximately
2 × 106 CFU/ml in serum-free medium (without antibiotics). 1 ml ali-
quots of bacteria were inoculated in triplicate onto washed confluent
monolayers (approx. 2 × 105 cells) in 24-well tissue culture trays and in-
cubated at 37 °C in 5% CO2 for 2 h. In addition, aliquots of wild type and
mutant bacteria were treated before inoculation with 2.5 μl of high titer
(1:50,000) polyclonal mouse anti-SpGlpO serum. Following adherence,
cell monolayers were washed 3 times with PBS and released and resus-
pended using 100 μl of 0.25% Trypsin-EDTA (Gibco; Cat No: 25200056)
for 2 min after which 400 μl of 0.025% Triton X 100 (Sigma; Cat No:
T8787) was added for 5 min to lyse Detroit 562 cells and release
bacteria. Sampleswere resuspended by repeated pipetting and adherent
bacteria were quantiated by serial dilution and plating on BA overnight
at 37 °C in 5% CO2. Assays were performed in triplicate in two indepen-
dent experiments. Differences between means were analyzed using the
unpaired Student's t-test (two-tailed).2.5. Glycan Array
Glycan arrayswere produced from a library consisting of 367diverse
glycanswith andwithout one of three spacers (sp2, sp3 or sp4) (Blixt et
al., 2004)made upof two previously described glycan libraries (Arndt et
al., 2011; Huflejt et al., 2009). Glycans were either amine functionalized
with spacers sp2, sp3 or sp4 as previously described (Blixt et al., 2004)
or without spacers as previously published (Day et al., 2009). Glycan ar-
rays were printed as previously published (Waespy et al., 2015). Glycan
array experiments were performed and analyzed as previously
described (Shewell et al., 2014) using 2 μg of purified SpGlpO per array.2.6. Surface Plasmon Resonance (SPR) Analyses
SPR analyses were performed using a Biacore T100 System (GE
Healthcare Life Sciences) at 25 °C at a flow rate of 30 μl permin. Purified
SpGlpOwas diluted to 50 μg perml in PBS and loaded on the appropriate
flow cells of a Ni2+ NTA sensor chip with 5min contact time. Flow cell 1
in each run contained an unrelated His-tagged protein, which was test-
ed to ensure it did not bindglycans, andwasused as a reference. Glycans
analyzed for interactionswith SpGlpOwere serially diluted from200 μM
to 0.32 μM in PBS and analyzed as previously described (Shewell et al.,
2014).2.7. Inhibition of Adherence by Sugars
Inhibition of adherence of wild type pneumococci and their isogenic
ΔglpOmutant derivatives to Detroit 562 cells by asialo-GM1 (aGM1; Cat
No: GLY102, Elicityl OligoTech) trisaccharide, lacto-N-neotetraose
tetrasaccharide (LNnT; Cat No: GLY021, Elicityl OligoTech) and lacto-
N-tetraose tetrasaccharide (LNT; Cat No: GLY010, Elicityl OligoTech)
was carried out as follows. Each bacterial strain (2 × 105 CFU) was
pre-incubated with 560 μM of each sugar (in duplicate) for 2 h at
37 °C in 5% CO2 before addition to duplicate Detroit 562 cell monolayers
in 24 well plates containing 2 × 104 cells in antibiotic-free 1:1 DMEM
and Ham's F-12medium+10% FCS). Trays were incubated for a further
2 h at 37 °C in 5% CO2 after which monolayers were washed 3 times in
PBS and treated with 25 μl of 0.25% Trypsin for 2 min and then 100 μl
of 0.025% Triton X-100 for 5 min. Samples were then plated on BA and
incubated overnight at 37 °C in 5%CO2 for bacterial enumeration. Assays
were performed in duplicate in two independent experiments. Dif-
ferences betweenmeanswere analyzed using the unpaired Student's
t-test (two-tailed).
Fig. 1. Competition between wild type and their isogenic ΔglpO mutant derivatives for
nasopharyngeal colonization. Results are expressed as the ratio of S. pneumoniaeWCH16
(serotype 6A), WCH43 (serotype 4), and their isogenic ΔglpOmutant derivatives in the
nasopharynx of mice at 48 h and 72 h post-infection. (a), WCH16 vs WCH16ΔglpO
mutant; (b), WCH43 vsWCH43ΔglpOmutant. 14–16 female CD1 mice were infected i.n.
with equal numbers (approx. 2.5 × 106 CFU each) of WT and mutant in each
experiment. Each datum point represents the ratio of recovered mutant bacteria to wild
type. The horizontal broken line represents a 1:1 ratio of recovered mutant bacteria. The
horizontal solid line denotes the geometric mean value of the ratio of recovered mutant
bacteria for each comparison (**** P b 0.0001; one sample t-test; two-tailed).
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Proteins
A series of N- and C-terminal His6-tagged truncated fragments of
SpGlpO were constructed by PCR-amplification from WCH43 DNA and
cloning into pQE31. The position of each fragment was guided by the
Coils prediction algorithm (Lupas et al., 1991). In addition, the NanA
open reading frame from S. pneumoniae D39 (excluding the LPXTG an-
choring motif at the C-terminus) was amplified using primers nanA F
(5′-GATTGTAGGATCCGTGGTATTTGGAACG-3′) and nanA R (5′-
GTGCCTGCAGAGCAAGAGGAGCTTTG-3′), incorporating BamHI and PstI
restriction sites (underlined), respectively. The PCR product was
digested with the restriction enzymes and cloned into the correspond-
ing restriction sites in pQE30. Each recombinant plasmid construct
was then used to transform E. coli BL21 (DE3) lpxM− strain (Cognet et
al., 2003). High-level expression of His6- tagged NanA, SpGlpO and
SpGlpO adjunct proteins was achieved by the addition of 2 mM isopro-
pyl-β-D-thiogalactopyranoside (IPTG; ThermoFisher Scientific, Cat No:
15529019) for 3 h at 37 °C. The cloning and expression of His6-tagged
MalX as well as PspA and PspC protein fragments has been described
previously (Ogunniyi et al., 2012; Ogunniyi et al., 2001; Yother and
Briles, 1992). Each recombinant protein or fragment was then purified
by nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography
(Qiagen, Cat No: 30210), as described previously (Ogunniyi et al.,
2007). Each purified protein was judged to be N98% pure by SDS-
PAGE and Coomassie blue staining (not shown).
2.9. Immunization Studies
For i.n. immunization-challenge, female CD1 mice (12–14 per
group) were immunized with purified SpGlpO, SpGlpO adjunct, MalX,
NanA, PspA fragment or PspC fragment, formulated with E. coli heat-la-
bile toxin (LTB) adjuvant. Each mouse received three doses of 10 μg of
each antigen with 2 μg of LTB at 10-day intervals (LTB was omitted for
the last immunization). Non-immunized mice received an identical
course of saline plus LTB. Oneweek after the last immunization, approx-
imately 75 μl saliva was collected from eachmouse after intraperitoneal
injection of 200 μg of pilocarpine-HCl (Sigma; Cat No: P6503), and
approximately 120 μl serum was obtained from individual mice by
sub-mandibular bleeding 3 days later. Twoweeks after the third immu-
nization,micewere challenged i.n.with approx. 5 × 106 CFU (in 20 μl) of
either wild type WCH16 or WCH43 by microtip instillation into both
nareswithout anesthesia. At 72 h post-challenge, micewere euthanized
and bacteria from the nasopharynx (nasal wash and nasal tissue) were
enumerated as described previously (McAllister et al., 2011). Differ-
ences in nasopharyngeal colonization between groups were analyzed
using the unpaired t-test (two-tailed). A P value of b0.05 was consid-
ered statistically significant.
2.10. Immunogenicity ELISA
For this assay, 0.045 μMof each protein or protein fragment was used
to coat Nunc Maxisorb trays (Thermo Scientific; Cat No: M9410-1CS).
Antigen-specific ELISA IgG titers were determined for pooled sera from
each group and expressed as the reciprocal of the dilution giving 50% of
the highest absorbance reading above the background at A405 nm. Total
salivary IgA levels were determined per 50 μl of pooled saliva per group
at A405 nm. Differences in salivary IgA levels between groups were ana-
lyzed by one-way ANOVA using Dunnett's multiple comparisons test. A
P value of b0.05 was considered statistically significant.
The potential contribution of a T-cell-mediated immune response
was also investigated by antigen restimulation of immune spleen cells.
For this assay, splenocytes from 3 mice from LTB, SpGlpO, SpGlpO ad-
junct or MalX-immunized group were harvested and concentrations
of IFN-γ, interleukin (IL)-6, IL-10 and IL-17Aweremeasured in superna-
tants of antigen-stimulated splenocytes at 72 h by sandwich ELISA,using mouse ELISA Ready-SET-Go kits (eBioscience; Cat Nos 88-7314-
88, 88-7064-88, 88-7104-88, 88-7371-88, respectively), essentially as
described recently (Babb et al., 2016). Concanavalin A was used as a
control, and concentrations of cytokines in supernatants were deter-
mined relative to the standard curve generated using cytokine stan-
dards provided by the manufacturer.
3. Results
3.1. A ΔglpO Mutant is Significantly Attenuated for Adherence
To examine the contribution of SpGlpO to nasopharyngeal coloniza-
tion, we carried out competition experiments in which groups of mice
were challenged i.n. with approximately equal numbers of wild type S.
pneumoniae strains WCH16 (serotype 6A) or WCH43 (serotype 4) and
their respective ΔglpO mutant derivatives. This enabled evaluation of
subtle differences between wild type and mutant by calculating the
competitive index for each mutant in the nasopharynx at 48 and 72 h
post-infection. We found that the ΔglpOmutant was significantly out-
competed by wild type in the nasopharynx at both time points in both
strains, with the WCH16ΔglpO mutant substantially out-competed
(N200 fold) by the wild type for adherence (Fig. 1).
In order to complement the in vivo observations, the ability of
WCH16 and WCH43 and their otherwise isogenic ΔglpOmutant coun-
terparts to adhere to human nasopharyngeal carcinoma epithelial (De-
troit 562) cells was assessed. In this assay, the ΔglpOmutant of WCH16
had significantly reduced adherence to Detroit 562 cells relative to wild
type (P b 0.001) (Fig. 2a); adherence was also attenuated when wild
type bacteria were pre-incubated with anti-SpGlpO serum
(P b 0.0001). Similarly (albeit to a lesser extent), the ΔglpOmutant of
WCH43 had significantly reduced adherence to Detroit 562 cells relative
to wild type (P b 0.01) as did wild type WCH43 pre-incubated with
polyclonal anti-SpGlpO serum (P b 0.05) (Fig. 2b).
3.2. SpGlpO Interacts With Glycans
Given the clear indication for a role for SpGlpO in nasopharyngeal
colonization in the mouse carriage and in vitro adherence studies, we
Fig. 2. Adherence to Detroit 562 nasopharyngeal carcinoma epithelial cells. Adherence of wild type WCH16 (a), WCH43 (b) and their isogenic ΔglpOmutant derivatives to Detroit 562
monolayers was assayed, with and without pre-incubation with anti-SpGlpO serum, as described in Materials and Methods. The number of adherent bacteria for each treatment was
determined in triplicate. Data (mean ± SEM) were analyzed using Student's t-test (two-tailed). *P b 0.05; **P b 0.01; ***P b 0.001; ****P b 0.0001.
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host-pathogen interaction. The data obtained in the colonization studies
raised the possibility that there is a receptor for SpGlpO on hostmucosal
surfaces. Using glycan array analysis,we investigated the glycan binding
specificities of purified SpGlpO on an array comprising 367 distinct gly-
cans. The SpGlpO bound to 57 of the 367 structures on the array, mostly
lactose/neolactose/ganglioside structures with a range of modifications
including sulfation, sialylation and fucosylation (Table S2). The SpGlpO
also bound to mannobiose structures and N-acetylglucosamine and
the glycosaminoglycan hyaluronic acid.
To validate the glycan array results and characterize the interaction
of SpGlpO with glycans, we performed surface plasmon resonance
(SPR) analysis with the core structures recognized. The interactions
with SpGlpO and glycans were strongest with the lacto/neolacto/
ganglio structures, particularly asialo-GM1 (aGM1) trisaccharide,
lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT)
tetrasaccharides, with interactions in the low micromolar range, while
interactions with mannose and N-Acetylglucosamine were weaker
(N100 μM) affinity (Table 1; Fig. S1). Pre-incubation of wild type
WCH16 with 560 μM aGM1 or LNnT significantly reduced adherence
to Detroit 562 cells (P b 0.05 in both cases). However, when
WCH16ΔglpO cells were pre-incubated with the sugars, the level of ad-
herencewas not significantly affected (Fig. 3a), demonstrating a specific
role for SpGlpO-glycan interactions in adherence to nasopharyngeal
epithelial surfaces. Pre-incubation of wild type WCH43 with aGM1
also significantly inhibited adherence (P b 0.01), but this did not occur
when WCH43ΔglpO cells were tested. There was, however, a small but
significant increase in adherence of WCH43ΔglpO cells pre-incubated
with LNnT (Fig. 3b).Table 1
Affinity of S. pneumoniae GlpO for a range of glycans.
Name Structure KD
asialoGM1 (aGM1) Galβ1-3GalNAcβ1-4Galβ1-4Glc 15.1 μM ± 1.3
Lacto-N-neotetraose (LNnT) Galβ1-4GlcNAcβ1-3Galβ1-4Glc 5.1 μM ± 0.45
Lacto-N-tetraose (LNT) Galβ1-3GlcNAcα1-3Galβ1-4Glc 6.3 μM ± 0.78
α1-2 mannobiose Manα1-2Man 279.6 μM ± 36
N-acetylglucosamine (GlcNAc) GlcNAc 154 μM ± 273.3. GlpO Modeling
To date, attempts to crystallize SpGlpO in both the full-length and
truncated forms have been unsuccessful. However, based on the avail-
able structure of GlpO from a Streptococcus sp. that has a 62% amino
acid identity to SpGlpO (PDB ID 2RGO) (Colussi et al., 2008), a 3-dimen-
sional model of SpGlpO was obtained with 100% confidence using
PHYRE2 (Kelley and Sternberg, 2009). The GlpO model incorporated
all amino acid residues with the exception of a 54 residue insert
(amino acids 362–415) that is associated with the absent flexible sur-
face region of the Streptococcus sp. GlpO structure and thus was unable
to be accurately modeled.
The GlpO model along with SwissDock (Grosdidier et al., 2011a, b)
was used to predict the binding sites of the aGM1 trisaccharide, as
well as LNnT and LNT tetrasaccharides, with the binding modes
consisting of the top 5most favorable energies assessed (Fig. 4). One re-
gion stood out as a potential binding site candidate where 10 of the top
15 sites among the three ligands were favored. This potential binding
site encompasses mostly loop and linker regions in a deep cleft that ap-
pears to fit multiple sugar residues, with the reducing carbohydrate hy-
droxyl residue at position C1 protruding to the solvent to accommodate
additional sugars that would be required to attach the oligosaccharide
to the host cell via a protein or lipid.3.4. Immunization of Mice With SpGlpO Protects Against Nasopharyngeal
Colonization
Given the findings of the in vivo and in vitro assays with the ΔglpO
mutant, we examined by i.n immunization-challenge experiments if
SpGlpO can protect against nasopharyngeal colonization, using recom-
binant MalX, NanA, PspA and PspC as comparators. These proteins
have been shown previously to protect against colonization in various
animal models (Balachandran et al., 2002; Moffitt et al., 2011; Tong et
al., 2005; Wu et al., 1997).
In order to determine the immunodominant fragment of SpGlpO,we
initially characterized the B-cell regions of SpGlpO by constructing a se-
ries of N- and C-terminal fragments of SpGlpO and assessing their im-
munogenicity by ELISA, leading to the construction of the SpGlpO
adjunct (Fig. S2). ELISA analysis of saliva samples frommice immunized
with SpGlpO, SpGlpO adjunct, NanA, PspA and PspC mice showed
Fig. 3. Inhibition of adherence of pneumococci by asialo-GM1 (aGM1) trisaccharide, lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT) tetrasaccharides. Wild type WCH16 (a),
WCH43 (b) and their isogenic ΔglpOmutant derivatives were pre-incubated with 560 μM of each sugar (in duplicate) for 2 h at 37 °C in 5% CO2 before addition to duplicate Detroit
562 cell monolayers. The number of adherent bacteria for each treatment was determined using 2 biological replicates for each treatment. Data (mean ± SEM) were analyzed using
Student's t-test (two-tailed). NS, Not significant; *P b 0.05; **P b 0.01.
240 L.K. Mahdi et al. / EBioMedicine 18 (2017) 236–243negligible IgA detection, with only MalX-immunized mice eliciting a
strong IgA response (Fig. S3). However, there was a significant total
IgG response from mice immunized with all the antigens (not shown).
Furthermore, higher interferon-gamma (IFN-γ) and interleukin (IL)-
17A (but not IL-6 or IL-10) responses were obtained in supernatants
of SpGlpO, SpGlpO adjunct and MalX-stimulated splenocytes relative
to E. coli heat-labile toxin B subunit (LTB)-stimulated splenocytesFig. 4. (a) SwissDock experiments with the GlpOmodel and its ligands (LNT in yellow, LNnT in
carbohydrate ligands as sticks. (b) A predicted bindingmode for LNTwith a surface representat
longer oligosaccharide from a host cell receptor. Red and blue sticks and surface representation
Cartoon representation of SpGlpO with the SpGlpO adjunct shown in green and the truncatio
nitrogen, and phosphate are colored red, blue, and orange.(data not shown). Importantly, mice immunized with SpGlpOwere sig-
nificantly protected against i.n. challengewith eitherWCH16 orWCH43
compared to the placebo group, as judged by reduction in CFU counts of
bacteria harvested from the nasopharynx. Protection against coloniza-
tionwas similar to (and in some cases better than) that achieved by im-
munization with MalX, NanA, PspA or PspC, antigens known to play a
role in colonization (Fig. 5).green, and asialo-GM1 in magenta). SpGlpO is shown as a surface representation and the
ion of the GlpOmodel. The arrow indicates where additional sugar residueswould be on a
s correspond to oxygen and nitrogen, respectively. (c) Truncations for the SpGlpO adjunct.
ns shown in grey. FAD was modeled into the active site and is shown as sticks. Oxygen,
Fig. 5.Mucosal immunization and challenge. The abilities of wild type WCH16 (a) and WCH43 (b) to colonize the nasopharynx of female CDI mice (12–14 per group) after intranasal
immunization with various recombinant pneumococcal proteins, as detailed in Materials and Methods. The E. coli heat-labile toxin (LTB) was used as the adjuvant. Mice were
challenged with pneumococci two weeks after the third immunization and were sacrificed 72 h after challenge to enumerate colonizing bacteria. Differences in levels of
nasopharyngeal colonization between control LTB immunization alone and vaccine groups were analyzed by unpaired t-test (two-tailed). NS, Not significant; *P b 0.05; **P b 0.01. The
horizontal solid line denotes the geometric mean counts of recovered bacteria for each group. The horizontal broken line represents limit of detection of bacteria (40 CFU).
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In this work we carried out a detailed molecular analysis of
SpGlpO, examined its role in the host-pathogen interaction during
nasopharygeal colonization, and also assessed its vaccine potential
against colonization. Our results suggest that SpGlpO, a conserved
protein expressed by all pneumococcal strains, plays a significant
role not only in meningitis, as we have previously described
(Mahdi et al., 2012), but also in adherence and subsequent coloniza-
tion of the nasopharynx through binding of specific host glycans. We
also show that intranasal immunization with recombinant SpGlpO
significantly protects mice against subsequent nasal carriage at
levels similar to that seen with other protein vaccine candidates, es-
pecially MalX (Moffitt et al., 2011). A recent study also demonstrated
significant protection against pneumonia and sepsis using a combina-
tion of SpGlpO and PncO (a bacteriocin ABC transporter transmembrane
protein) (Li et al., 2016), indicating that SpGlpO has promise as a pan-
serotype vaccine candidate.
It has been established that pneumococcal adherence factors differ-
entially bind to specific epithelial cell receptors onmammalian cells and
tissues (Andersson et al., 1981; Svanborg Eden et al., 1984), with specif-
ic binding to glycoconjugate receptors containing the GlcNAcβ1-3Galβ
disaccharide on nasopharyngeal cells (Andersson et al., 1983; Tong et
al., 1999) and the GalNAcβ1-4Gal disaccharide on lung and vascular en-
dothelial cells (Cundell and Tuomanen, 1994; Krivan et al., 1988). There
has been evidence that S. pneumonaie binds to GalNAcβ1-4Gal through
the phosphoryl choline residue of the C-polysaccharide, a major surface
component of the pneumococcus (Sundberg-Kovamees et al., 1996).
However, to our knowledge the pneumococcal binding partner for
GlcNAcβ1-3Gal has yet to be identified.
We found that SpGlpO interacts with a wide range of host glycans
with the strongest binding to those that are commonly found as O-
linked glycans of protein glycosylation and as lactoceramides/ganglio-
sides. In addition, asialo-GM1contains the coreGalNAcβ1-4Gal suggest-
ing that SpGlpO is an alternative binding partner for these gangliosides,
with this interaction proving important inmediating pneumococcal ad-
herence to nasopharyngeal cells. Given these findings, we propose that
SpGlpO enhances pneumococcal colonization of the nasopharynx
through its direct binding to host glycoconjugates. In this context, the
use of oligosaccharides to block pneumococcal adherence to mucosal
surfaces presents an attractive prospect for therapy and disease preven-
tion, as demonstrated for LNnT using a rabbit model of pneumonia and
bacteremia and an infant rat model of colonization (Idanpaan-Heikkila
et al., 1997).GlcNAcβ1-3Gal is a core structure of gangliosides, which are pre-
dominantly found on neuronal surfaces. Previouswork has demonstrat-
ed a ganglioside-mediated colonization of the nasopharynx and brain
by pneumococci (van Ginkel et al., 2003). We previously reported that
an SpGlpOmutant showed decreased adherence to human brainmicro-
vascular endothelial cells (Mahdi et al., 2012), although a detailed
mechanism for this was not determined. This study suggests that the
binding of SpGlpO to different gangliosides, like asialo-GM1, could facil-
itate attachment to brain cells, providing an alternative mechanism for
pneumococcal attachment to brain tissue. Interestingly, this would sug-
gest an additional role for SpGlpO, along with its hydrogen peroxide
producing cytotoxic effects, in the pathogenesis of pneumococcal men-
ingitis. Moreover, the binding of SpGlpO to gangliosides opens up the
likelihood that such interactions play a major role in the pathogenesis
of otitis media, as was previously shown in chinchilla tracheal epithelia
(Tong et al., 1999), and in gerbils where CNS infection occurred after
pneumococcal otitis media (Muffat-Joly et al., 1994).
Immune-mediated clearance of pneumococci from the nasopharynx
involves both antibody-dependent and antibody-independent mecha-
nisms (Goldblatt et al., 2005; Malley et al., 2007; van Rossum et al.,
2005). Antibody-independent clearance is thought to involve an IL-
17A-mediated T-cell response, resulting in the recruitment of neutro-
phils to the site of infection and subsequent clearance of colonization
(Lu et al., 2008;Malley et al., 2006). Consistentwith these reports, intra-
nasal immunization of mice with SpGlpO or SpGlpO-adjunct elicited
significant total serum IgG, negligible salivary IgA, and more IFN-γ and
IL-17A responses comparedwith LTB controls. Thefinding that immuni-
zation with SpGlpO did not completely block colonization could be
advantageous in the context of reducing colonization to levels that sig-
nificantly impacts on overall pneumococcal translocation to deeper host
tissues,while intra- and inter-species competition in the nasopharynx is
maintained at asymptomatic levels. This is also likely to result in
reduction in transmission from carriers to new hosts. Our previous
work with WCH16 and WCH43 showed that stable colonization of the
nasopharynx of CD1 (Swiss) mice was firmly established over a 48- to
96-h period,with optimal anduniform colonization at 72hpost-infection
(Mahdi et al., 2012). This finding led us to choose 72 h after challenge as
the ideal time-point for mouse sacrifice to determine the level of
nasopharyngeal colonization.
In summary, we provide evidence for a direct contribution of SpGlpO
to colonization of the nasopharynx through its binding to host
glycoconjugates, and show that intranasal immunization of mice with
SpGlpO elicited significant protection against subsequent nasal coloni-
zation. We conclude that SpGlpO warrants consideration for inclusion
242 L.K. Mahdi et al. / EBioMedicine 18 (2017) 236–243in an optimal, multi-component protein vaccine formulation that can
provide robust, serotype-independent protection against nasopharyn-
geal colonization and all forms of invasive pneumococcal disease.
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